AstraZeneca plc (AZN) Trading 0.3% Higher Following Analyst Upgrade
AstraZeneca plc (LON:AZN) shares traded up 0.3% during trading on Monday after HSBC Holdings plc raised their price target on the stock from GBX 4,100 to GBX 4,150. HSBC Holdings plc currently has a reduce rating on the stock. AstraZeneca plc traded as high as GBX 5,172 ($68.00) and last traded at GBX 5,172 ($68.00). 1,337,510 shares traded hands during trading, a decline of 48% from the average session volume of 2,594,000 shares. The stock had previously closed at GBX 5,154 ($67.76).
AZN has been the subject of a number of other reports. UBS AG set a GBX 5,150 ($67.71) price target on AstraZeneca plc and gave the stock a “neutral” rating in a research report on Tuesday, June 27th. J P Morgan Chase & Co restated a “neutral” rating on shares of AstraZeneca plc in a research report on Thursday, July 13th. Credit Suisse Group lowered their price target on AstraZeneca plc from GBX 5,000 ($65.74) to GBX 4,700 ($61.79) and set a “neutral” rating for the company in a research report on Friday, July 28th. Goldman Sachs Group, Inc. (The) set a GBX 3,900 ($51.28) price target on AstraZeneca plc and gave the stock a “sell” rating in a research report on Wednesday, August 2nd. Finally, Shore Capital restated a “hold” rating on shares of AstraZeneca plc in a research report on Wednesday, August 2nd. Three analysts have rated the stock with a sell rating, eight have given a hold rating and eleven have assigned a buy rating to the company. The company has an average rating of “Hold” and an average target price of GBX 5,113.55 ($67.23).
In related news, insider Nazneen Rahman bought 39 shares of the stock in a transaction dated Thursday, July 27th. The stock was bought at an average cost of GBX 4,370 ($57.45) per share, with a total value of £1,704.30 ($2,240.73).
The firm’s market capitalization is GBX 65.48 billion. The stock has a 50-day moving average of GBX 4,738.46 and a 200 day moving average of GBX 4,897.65.
The company also recently disclosed a dividend, which was paid on Monday, September 11th. Stockholders of record on Thursday, August 10th were issued a dividend of GBX 68.90 ($0.91) per share. This represents a dividend yield of 1.35%. The ex-dividend date was Thursday, August 10th.
ILLEGAL ACTIVITY NOTICE: This piece of content was first published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this piece of content on another publication, it was illegally stolen and reposted in violation of U.S. & international copyright and trademark law. The correct version of this piece of content can be accessed at https://www.thecerbatgem.com/2017/10/09/astrazeneca-plc-azn-trading-0-3-higher-following-analyst-upgrade.html.
About AstraZeneca plc
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.
Receive News & Stock Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related stocks with our FREE daily email newsletter.